Hemopatch Safety and Efficacy Evaluation Versus Standard Practice for Sealing the Dura in Cerebrospinal Fluid Leaks

Surgery Clinical Trial

Official title:

Randomized Multicenter Controlled Study to Evaluate the Safety and Efficacy of HEMOPATCH® Compared to Routine Care for Dural Closure as Reinforcement for the Prevention of Postoperative Cerebrospinal Fluid Leakage (CSF) in Patients Undergoing Posterior Fossa Surgery

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04419597
• Other study ID #: NEUROHEMOPATCH
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 2, 2020
• Est. completion date: November 30, 2023

Study information

• Verified date: May 2023
• Source: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Posterior fossa surgeries are generally complicated by difficulties in creating a watertight dural closure, which often requires the use of dural substitutes. In particular, surgical procedures at this location are associated with an increased rate of fluid leakage (cerebrospinal fluid (CSF)) or inflow (blood, air, etc.) creating hydrodynamic complications. Effective sealing of the dura is required to prevent such complications and infections by minimizing the introduction of irritating blood products into the CSF. Since true hermetic dural seals are often impossible to achieve, dural sealants have been developed that can be applied to the sutured dural perimeter to help prevent complications related to CSF. Adjuvant use of such sealants may be prudent, particularly in posterior fossa surgeries, as the incidence of CSF leakage has been reported to be as high as approximately 15-28% with such surgeries, with an increased risk of leakage. 5.84 times greater than supratentorial procedures.

Description:

Various techniques have been developed to overcome this problem and achieve a tight dural closure. Although there is published evidence showing the efficacy and safety of some of these sealants in posterior fossa surgery, the different types of pathologies and various population risk factors included in these trials make it difficult to interpret the results. Having selective inclusion criteria and including patients with a selected pathology could be essential to obtain clearer results.

Postoperative CSF leak has two aspects: one is pseudomeningocele (a subcutaneous collection of CSF); the other is a CSF fistula in which CSF reaches the skin. This second one is much more dangerous and constitutes one of the most important complications of this surgery, but the pseudomeningocele is a clinical demonstration of failure of the dural closure.

HEMOPATCH is a soft, thin, foldable and flexible collagen patch, coated with NHS-PEG. HEMOPATCH is indicated as a hemostatic device and surgical seal for procedures in which control of bleeding or leakage of other body fluids or air by conventional surgical techniques is ineffective or impractical.

Preliminary clinical evidence collects a prospective case series of 200 patients, in which the authors reviewed the use of HEMOPATCH for dural augmentation in high-risk patients from 2014 to this year. After 2 years of refining the technique, a decrease in CSF leaks from 27% to 7% was achieved, and no adverse events related to the application of the product were observed. A retrospective cohort study has recently been published comparing the use of HEMOPATCH versus routine clinical practice in 290 patients, in which 147 used standard dural reinforcement techniques, and 143 used HEMOPATCH. The CSF fistula appearance rates were 7.69% in the HEMOPATCH group, compared to 32.65% in the control group.

These recent results, along with the characteristics and properties of the patch, could make this sealant a safe and plausible option to achieve sealing after posterior fossa surgery.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 122
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who are planned for non-traumatic posterior fossa surgery

• Surgery that requires opening and closing of the dura mater.

• Patients who have a clean surgical wound (class I surgical wound classification)

• Patients undergoing one of the following surgical procedures:

• Space occupant injuries (LOEs) rese dried through the following approaches:

• Approaching the rear pit of the middle line

• Approach to the posterior paramedian fossa

• Approach to the cerebellar pontine angle (PC) and the back of the petrous vertex

• Clinical diagnosis of primary Chiari 1 (CM1) malformation and scheduled decompression surgery, with evidence of NM of tonsil herniation down by an independent official radiology report.

• Subjects who are able to provide written informed consent prior to participating in the clinical trial.

• Be over 18 years of age.

• Understand the purpose of the study and be available for frequent hospital visits.

• Women of childbearing potential and males with partners of childbearing potential should commit to using a highly effective method of contraception (such as surgical sterilization, double barrier method, oral contraceptives or contraceptive hormonal implants) and to continue to use them for up to 6 months after surgery.

Exclusion Criteria:

• Patients undergoing a supratentorial surgical procedure/approach.

• Patients undergoing any other approach/surgical procedure at the base of the skull that is not in the posterior pit:

• Side boarding of the foramen magno: far side, extreme side, anterolateral, posterolateral,

• Approaching the jugular foramen: infratemporal, condylar juxta, transjugular

• Approach to the middle pit: subtemporal (+/-petrous apex perforation), pterional approach (any temporary fronto approach +/- orbitozygomatic replacement)

• Approach to the previous pit: subfrontal (uni or bilateral)

• Presence of hydrocephalus not resolved prior to surgery

• Previous surgery in the posterior pit.

• Pre-radiation therapy treatment.

• Previous (within the last 6 months) or anticipated neurosurgical procedure involving the opening of the dura mater that may affect the safety assessment

• > 1 dural opening

• Inability to understand informed consent or unwillingness to participate in the study.

• Inability, at the time of consent, to return for follow-up evaluations after surgery

• Evidence of spinal dysraphism.

• Allergy, hypersensitivity or history of allergic reaction to Hemopatch or its components (to bovine proteins or bright blue dye: FD&C blue No. 1 [blue 1]).

• Evidence of an infection within 5 days prior to the start of the study.

• Pregnancy or planning to become pregnant during the course of the study. Breast feeding

Related Conditions & MeSH terms

• Surgery

Intervention

Device:
• HEMOPATCH
The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
• Standard of care
Usual clinical practice techniques for reinforcing primary dural closure.

Locations

Country	Name	City	State
Spain	Hospital Ramón y Cajal	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	proportion of participants with clinically evident CSF leak after the operation up to 4 weeks.	Clinically evident CSF leak, observed from the operation to 4 weeks later. It will be measured every 24 hours until the patient is discharged. The following measurement will be made at the visit of the 4 weeks (+/- 7 days) from the operation	4 weeks
Secondary	Proportion of participants with clinical pseudomeningocele or evident MRI	Clinical evidence of Pseudomeningocele or by imaging techniques, evaluated by CT or MRI during the 4 postoperative weeks, by MRI at 6 postoperative months, or at any visit of patients within 6 postoperative months according to the criteria of the investigator	6 months
Secondary	Proportion of participants with ascent of the cerebellar tonsils	The elevation of the cerebellar tonsils will be measured, according to the baseline preoperative CT / MRI, in the MRI test performed 6 months after the operation.	6 months
Secondary	Proportion of participants with readmissions related to CSF leaks	The need for readmission / reoperation related to CSF leak will be collected up to 4 weeks after the operation.	4 weeks
Secondary	Number of Participants with Surgical site infections (SSI)	Bacterial or chemical meningitis (SSI)	4 weeks
Secondary	Assessment of quality of life (QoL): SF12 questionnaire (Short Form 12 questionnaire)	The SF-12 measures overall quality of life and includes items that assess participation. The SF-12 is a frequently used measure and has shown to have good internal consistency, reliability, construct validity and responsiveness in patients with chronic (low) back pain (Luo et al., 2003). The measure is a subset of 12 items from the SF-36 including 6 items from the physical summary measure (PCS) and 6 items from the mental summary measure (MCS).	6 months